Bristol Myers reports positive two-year Sotyktu data

On 18 September 2026, reports highlighted positive two-year results from Bristol Myers Squibb's late-stage POETYK PsA-2 study and open-label extension for Sotyktu. The oral TYK2 inhibitor maintained durable clinical responses in adults with active psoriatic arthritis from week 16 through week 104 across key measures, including ACR20, ACR50, ACR70, and Minimal Disease Activity.

The long-term safety profile showed no new safety signals across 604 treated patients. Adverse events occurred in 86.6% of patients, serious adverse events were recorded in 12.6%, and 7.6% discontinued treatment due to adverse events. Sotyktu generated $156 million in revenue during the first half of 2026, marking a 24% increase year over year following its regulatory approval for psoriatic arthritis earlier in the year.

Bristol Myers is working to expand Sotyktu into systemic lupus erythematosus and Sjögren's disease, with POETYK SLE-1 and SLE-2 trial data expected later in 2026. The therapy faces market competition from Amgen's Otezla as well as Takeda's investigational oral TYK2 inhibitor zasocitinib, which recently had its new drug application accepted by the US FDA for plaque psoriasis.

Shares of Bristol Myers have risen 16.5% year to date, outperforming the industry average increase of 5.7%. The stock trades at 9.58 times forward earnings, below the large-cap pharma industry average of 18.01 times but above its historical mean of 8.70 times.